- Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective
-
Su TH, Wu CH, Liu TH, Ho CM, Liu CJ
- KMID: 2541402
- Clin Mol Hepatol.
- 2023 Apr;29(2):230-241.
- doi: 10.3350/cmh.2022.0421
Hepatocellular carcinoma (HCC) is the fourth most common cancer and the second leading cause of cancer-related death in Taiwan. The Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan... -
- CITED
-
- Close
- SHARE
-
- Close
- Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives
-
Huang SC, Liu CJ
- KMID: 2541408
- Clin Mol Hepatol.
- 2023 Apr;29(2):320-331.
- doi: 10.3350/cmh.2022.0422
The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) has increased among the general population and chronic hepatitis B (CHB) patients worldwide. Although fatty liver disease is a well-known risk... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease
-
Huang SC, Su HJ, Kao JH, Tseng TC, Yang HC, Su TH, Chen PJ, Liu CJ
- KMID: 2515849
- Gut Liver.
- 2021 May;15(3):451-458.
- doi: 10.5009/gnl20218
Background/Aims: Fatty liver disease is defined as a cluster of diseases with heterogeneous etiologies, and its definition continues to evolve. The novel conceptional criteria for metabolic dysfunction-associated fatty liver disease... -
- CITED
-
- Close
- SHARE
-
- Close
- Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives
-
Su TH, Liu CJ
- KMID: 2389346
- Gut Liver.
- 2017 Sep;11(5):590-603.
- doi: 10.5009/gnl16215
Nucleos(t)ide analogues (NUCs) and interferon have been used for several decades to treat chronic hepatitis B; however, the therapeutic response remains unsatisfactory. Although NUC therapy exhibits potent on-treatment viral suppression,... -
- CITED
-
- Close
- SHARE
-
- Close
- Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases
-
Cheng PN, Chen WJ, Hou CJY, Lin CL, Chang ML, Wang CC, Chang WT, Wang CY, Lin CY, Hung CL, Peng CY, Yu ML, Chao TH, Huang JF, Huang YH, Chen CY, Chiang CE, Lin HC, Li YH, Lin TH, Kao JH, Wang TD, Liu PY, Wu YW, Liu CJ
- KMID: 2549381
- Clin Mol Hepatol.
- 2024 Jan;30(1):16-36.
- doi: 10.3350/cmh.2023.0315
Metabolic dysfunction-associated fatty liver disease (MAFLD) is an increasingly common liver disease worldwide. MAFLD is diagnosed based on the presence of steatosis on images, histological findings, or serum marker levels... -
- CITED
-
- Close
- SHARE
-
- Close
- Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
-
Liu CH, Chen CY, Su WW, Liu CJ, Lo CC, Huang KJ, Chen JJ, Tseng KC, Chang CY, Peng CY, Shih YL, Huang CS, Kao WY, Yang SS, Tsai MC, Wu JH, Chen PY, Su PY, Hwang JJ, Fang YJ, Lee PL, Tseng CW, Lee FJ, Lai HC, Hsieh TY, Chang CC, Chang CH, Huang YJ, Kao JH
- KMID: 2520841
- Clin Mol Hepatol.
- 2021 Oct;27(4):575-588.
- doi: 10.3350/cmh.2021.0155
Background/Aims: Real-world studies assessing the effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) plus ribavirin (RBV) for Child-Pugh B/C hepatitis C virus (HCV)-related cirrhosis are limited. Methods: We included 107 patients with Child-Pugh... -
- CITED
-
- Close
- SHARE
-
- Close
- Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program
-
Lu MY, Huang CF, Hung CH, Tai C, Mo LR, Kuo HT, Tseng KC, Lo CC, Bair MJ, Wang SJ, Huang JF, Yeh ML, Chen CT, Tsai MC, Huang CW, Lee PL, Yang TH, Huang YH, Chong LW, Chen CL, Yang CC, Yang S, Cheng PN, Hsieh TY, Hu JT, Wu WC, Cheng CY, Chen GY, Zhou GX, Tsai WL, Kao CN, Lin CL, Wang CC, Lin TY, Lin C, Su WW, Lee TH, Chang TS, Liu CJ, Dai CY, Kao JH, Lin HC, Chuang WL, Peng CY, Tsai CW, Chen CY, Yu ML, TACR Study Group
- KMID: 2549384
- Clin Mol Hepatol.
- 2024 Jan;30(1):64-79.
- doi: 10.3350/cmh.2023.0287
Background/Aims: Despite the high efficacy of direct-acting antivirals (DAAs), approximately 1–3% of hepatitis C virus (HCV) patients fail to achieve a sustained virological response. We conducted a nationwide study to... -
- CITED
-
- Close
- SHARE
-
- Close
